Scholar Rock (SRRK) Leerink Global Healthcare Conference 2026 summary
Event summary combining transcript, slides, and related documents.
Leerink Global Healthcare Conference 2026 summary
28 Mar, 2026Clinical and regulatory progress
Achieved positive phase III SAPPHIRE trial results for apitegromab in SMA, meeting primary endpoints with significant motor function improvement in patients on SMN-targeted therapies.
Filed for approval in January 2025 and received priority review with an action date of September 22, 2025.
Approval delayed due to compliance issues at the fill-finish facility in Indiana, now owned by Novo Nordisk; a Type A meeting with FDA in November 2025 established a collaborative remediation plan.
FDA issued a warning letter to Novo Nordisk, which responded promptly, leading to a positive site visit and plans for a formal re-inspection after resumption of manufacturing.
Guidance reaffirmed for BLA resubmission and U.S. launch in 2026, pending successful re-inspection and regulatory review.
Manufacturing and supply chain
Progressing with a second fill-finish facility as a contingency, with engineering and validation runs underway to ensure supply redundancy.
Confident that both facilities will support a 2026 launch, with sufficient drug inventory already vialed and ready for market release.
Existing supply supports ongoing clinical trials and early access programs, with no need for additional manufacturing before launch.
Second facility expected to release product in 2026, further supporting supply chain resilience.
Commercial readiness and launch strategy
Commercial team hired, trained, and deployed, focusing on disease awareness and education at 140 SMA treatment centers.
Built a nationwide home infusion network and established ongoing payer engagement to facilitate access and reimbursement.
Launched patient assistance and disease awareness programs to support uptake and patient navigation at launch.
Anticipates initial reimbursement challenges but expects strong demand and conversion rates post-approval.
Latest events from Scholar Rock
- Broad early ISEMBYLD demand sets up U.S. expansion, global launches, and pipeline growth.SRRK
Jefferies Global Healthcare Conference - ISEMBYLD gains broad early uptake as global launches advance into 2027.SRRK
UBS Global Biopharma Conference 2026 - ISEMBYLD launched with $0.57M in Q3 revenue as access and global expansion advance.SRRK
Q3 2026 - FDA approves ISEMBYLD, the first muscle-targeted SMA therapy, with immediate U.S. launch.SRRK
FDA announcement - Apitegromab set for 2026 launch as first muscle-targeted SMA therapy, driving global expansion.SRRK
Corporate presentation - Apitegromab nears FDA approval as a first-in-class SMA therapy, with global launch plans underway.SRRK
Citigroup’s Biopharma Back to School Summit 2026 - FDA decision on apitegromab for SMA expected by September 30, with global launches planned.SRRK
12th Annual Cantor Fitzgerald Global Healthcare Conference - Apitegromab nears FDA approval with dual manufacturing paths and strong launch readiness.SRRK
Canaccord Genuity's 46th Annual Growth Conference - FDA decision on apitegromab expected by September 30, 2026, with strong cash reserves and launch readiness.SRRK
Q2 2026 - Apitegromab plus tirzepatide preserved lean mass and improved weight loss quality in obesity.SRRK
Study Update